2020

PUTRAJAYA, 17 July – VentureTECH today signed and exchanged a tripartite Memorandum of
Understanding (MoU) with Duopharma Biotech Bhd (Duopharma Biotech) and PanGen Biotech
Inc. (PanGen) toward the establishment of Malaysia’s first commercial biosimilar production
facility in a move to position the country as a regional player in the growing biosimilar market,
whilst improving affordability and accessibility to healthcare in the country.
The MoU signing ceremony was graced and witnessed by the Minister of Science, Technology,
and Innovation (MOSTI), YB Khairy Jamaluddin.

PUTRAJAYA, 17 July 2020 – VentureTECH today signed and exchanged a tripartite Memorandum of Understanding (MoU) with Duopharma Biotech Bhd (Duopharma Biotech) and PanGen Biotech Inc. (PanGen) toward the establishment of Malaysia’s first commercial biosimilar production facility in a move to position the country as a regional player in the growing biosimilar market, whilst improving affordability and accessibility to healthcare in the country.

Duopharma Biotech Berhad’s 19th – and first ever fully virtual – AGM reinforces the Group’s dynamic aim of evolving as a pharmaceutical and healthcare leader with significant milestones during its second year as an independent entity
Strong business fundamentals and core values of the Group are fuelling onward progress through the coronavirus crisis, said Duopharma Biotech leadership

Higher demand from private sectors fuels improved revenue figures
Group MD remains cautiously optimistic of FY2020 financial performance

Duopharma Biotech emerges into digital technology to provide Smarter Solution for a Healthier Life for all
Empowering Naluri’s Digital Health Platform constitutes another milestone in Duopharma Biotech’s innovation strategy

Duopharma Biotech together with Permodalan Nasional Berhad contribute Ventilators for a Government Hospital;
Three Patient Monitoring Devices, which will be used at the Intensive Care Unit (“ICU”) at Government Hospitals
RM10,000 cash was donated to Orang Asli through Epic Society
RM50,000.00 cash was channeled to Government-Linked Companies’ Disaster Response Network (“GDRN”) to purchase other supplies

KUALA LUMPUR, 13 February 2020 – In an announcement to Bursa Malaysia this evening,
Duopharma Biotech Berhad (formerly known as CCM Duopharma Biotech Berhad) (“Duopharma
Biotech” or “Company”) announced a commendable set of unaudited financial results to close off a
strong performance in 2019 with yearly net profit increasing 16 percent to touch RM55.27 million
(2018: RM47.64 million) on higher revenue of RM576.46 million (2018: RM498.72 million).